Tracking & Feedback Registry to Reduce Breast Cancer Treatment Disparities
Completed · Not applicable
Conditions studied: Breast Cancer
In brief
Breast cancer is the second most common cause of cancer death in women. Black women are less likely than white women to develop breast cancer but, they are more likely to die of the disease. Some of this survival discrepancy is likely due to underuse of adjuvant therapies proven to increase survival. Breast cancer treatment often requires coordination among surgeons, pathologists, primary care physicians, medical and radiation oncologists. In NYC, black and Hispanic women who accessed care and underwent surgical treatment of their breast cancer were twice as likely as whites to experience underuse of adjuvant treatment. Disturbingly, 1/3 of these underuse cases were episodes in which the surgeon recommended treatment, the patient did not refuse and yet, care did not ensue. Underuse in such circumstances is attributable to system failures than to specific provider or patient factors. In this proposed randomized controlled trial, the investigators aim to test the effectiveness of a Tracking and Feedback (T\&F) registry innovation to increase rates of completed oncology consultation and reduce both underuse of needed adjuvant therapy and racial disparities in receipt of these treatments. The investigators also aim to assess the feasibility of implementing a T\&F Registry in these high-risk hospitals by evaluating implementation effectiveness for that innovation. The investigators have recruited 10 hospitals that serve large proportions of minority women with breast cancer. The investigators will randomize hospitals and aim to recruit 354 women with a new breast cancer, 177 per intervention arm. The investigators choose these "high risk" hospitals because they serve predominantly minority populations, and such hospitals have higher rates of the system failure cause of underuse, and particularly, the type of underuse targeted by our Tracking and Feedback Registry.
Key facts
- Study ID
- NCT01544374
- Run by
- Icahn School of Medicine at Mount Sinai
- People needed
- 198
- Starts
- 2012-10-01
- Expected to finish
- 2016-05-01
- Last updated by the study team
- 2016-06-09
Who can join
Age: 21 and older. Sex: female. Healthy volunteers: not accepted.
You may qualify if…
- All patients, who are English or Spanish speaking, with a new primary stage 1 or 2 and with tumors > 1 cm or < 1 cm and poorly differentiated breast cancer who have undergone either breast conserving surgery or mastectomy at 1 of 10 participating hospitals in the NY Metropolitan Area.
- All surgeons performing breast surgery at study participating hospitals
You may not qualify if…
- Patients with a poor prognosis due to end-stage organ failure or other concomitant conditions such as those undergoing treatment for other cancers
Where it is running
- Newark Beth Israel Medical Center — Newark, New Jersey, United States
- Brooklyn Hospital Center — Brooklyn, New York, United States
- University Hospital of Brooklyn at Long Island College Hospital — Brooklyn, New York, United States
- Kings County Hospital — Brooklyn, New York, United States
- Lutheran Medical Center — Brooklyn, New York, United States
- Elmhurst Hospital Center — Elmhurst, New York, United States
- Queens Hospital Center — Jamaica, New York, United States
- Metropolitan Hospital Center — New York, New York, United States
- Bronx-Lebanon Hospital — The Bronx, New York, United States
- Jacobi Medical Center — The Bronx, New York, United States
- Montefiore Medical Center — The Bronx, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.